reports
- GlobalData Department
Great Basin Scientific Inc (GBSN) - Medical Equipment - Deals and Alli...
Summary Great Basin Scientific Inc (Great Basin) is a molecular diagnostics company that offers technology products. The company develops and distributes point-of-care technology and products to improve automation, throughput, scalability, reliability and ease-of-use in rapid diagnostic testing. It develops tests in the areas of staph, clostridium difficile, nasal MRSA and fungal pathogens. Great Basin’s diagnostic system is an integrated disposable cartridge including necessary reagents and ...
CORRECTINGÂ and REPLACINGÂ Great Basin Announces Effectiveness of Reve...
SALT LAKE CITY--(BUSINESS WIRE)-- First paragraph, second sentence of release should read: The Company’s common stock will begin trading at the open of today’s market on a split-adjusted basis under new CUSIP number 39013L601 (instead of ... new CUSIP number 39013L502). The corrected release reads: GREAT BASIN ANNOUNCES EFFECTIVENESS OF REVERSE STOCK SPLIT OF COMMON STOCK Company has 1.0 million shares of common stock outstanding post-split Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecu...
Great Basin Announces Reverse Stock Split of Common Stock
SALT LAKE CITY--(BUSINESS WIRE)-- Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that a 1-for-80 reverse split of its common stock will be effective at 12:01 am EDT on September 16, 2016. The Company’s common stock will open for trading on the Nasdaq Capital Market on September 16, 2016 on a post-split basis. At the effective time of the reverse stock split, every 80 shares of the Company’s issued and outstanding common stock, par value $0.0001, will be consolidated into one newly-issued a...
Great Basin Scientific Announces Annual Meeting Results
SALT LAKE CITY--(BUSINESS WIRE)-- Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today approval of all but one proposal during the 2016 Annual Meeting of Stockholders. Shareholders elected two members to the Board of Directors and approved the Series E Warrants Exchange, the Nasdaq 20% Issuance, and the Adjournment proposals. Shareholders also approved a reverse stock split and ratified the appointment of the Company’s independent registered public accounting firm. Shareholders did not approve a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.